Pharmacological modulation by 1,4-dihydropyridines is a central feature of L-type calcium channels. Recently, eight L-type amino acid residues in transmembrane segments IIIS5, IIIS6, and IVS6 of the calcium channel ␣ 1 subunit were identified to substantially contribute to 1,4-dihydropyridine sensitivity. To determine whether these eight L-type residues (Thr Voltage-dependent calcium channels are activated by membrane depolarization and mediate the rapid and selective entry of calcium into excitable cells. The subsequent rise in intracellular calcium triggers a variety of cellular responses, including excitation-contraction coupling, excitation-secretion coupling, synaptic plasticity, and the modulation of transcription events (for a review, see Refs. 1 and 2). On the basis of electrophysiological and pharmacological criteria, voltage-dependent calcium channels are classified into L-, N-, T-, P/Q-, and R-type channels (reviewed in Refs. 3 and 4). The heterooligomeric channel complexes are composed of a pore-forming ␣ 1 subunit in combination with accessory subunits (␣ 2 ␦, , and in skeletal muscle ␥), which modulate the pharmacological and kinetic channel properties (1, 4). Molecular cloning and heterologous expression experiments have revealed that three classes of ␣ 1 subunits (␣ 1C (5) in heart, smooth muscle, and neurons; ␣ 1S (6) in skeletal muscle; and ␣ 1D (7) in neuroendocrine cells) form L-type calcium channels (3). They are distinguished from the other types by their high sensitivity to 1,4-dihydropyridines, phenylalkylamines, and benzothiazepines (8), which are used therapeutically for the treatment of a variety of cardiovascular disorders (9). 1,4-Dihydropyridine (DHP) 1 antagonists stabilize the inactivated state of the channel (10), whereas DHP agonists promote the open state (11). However, the molecular mechanism of channel modulation mediated by these drugs has yet to be completely elucidated.The DHP binding domain is located on the ␣ 1 subunit (12). It is tightly coupled to a high affinity calcium binding site (13) representing the ion selectivity filter (14 -16). One essential requirement to fully understand the molecular mechanism of channel modulation is the identification of amino acid residues that mediate DHP agonist and antagonist effects. Photoaffinity labeling, combined with antibody mapping (12) as well as construction of chimeric ␣ 1 subunits (17) identified parts of the high affinity DHP binding domain. Using a gain-of-function approach, we have shown that introducing only as little as 9.4% L-type sequence (including transmembrane segments IIIS5, IIIS6, and IVS6) is sufficient to transfer DHP sensitivity to the DHP-insensitive class A (BI-2) calcium channel ␣ 1 subunit (18). Subsequently, we demonstrated that two amino acid residues of segment IIIS5 are critical for the DHP interaction (19). In transmembrane segments IIIS6 and IVS6 of the ␣ 1 subunit, six other L-type amino acid residues were identified to be required for DHP binding by creating chimeras and mutants that were monito...